US 12,390,431 B2
Method of escalating sotalol hydrochloride dosing
John Charin Somberg, Chicago, IL (US); Brandon Ira Kashfian, Chicago, IL (US); and Janos Molnar, Chicago, IL (US)
Assigned to AltaThera Pharmaceuticals LLC, Chicago, IL (US)
Filed by AltaThera Pharmaceuticals LLC, Chicago, IL (US)
Filed on Nov. 24, 2019, as Appl. No. 16/693,312.
Application 16/693,312 is a continuation of application No. 16/103,815, filed on Aug. 14, 2018, granted, now 10,512,620.
Prior Publication US 2020/0085771 A1, Mar. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/18 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61P 9/06 (2006.01)
CPC A61K 31/18 (2013.01) [A61K 9/0019 (2013.01); A61P 9/06 (2018.01)] 11 Claims
 
1. A method of rapidly escalating a subject's oral sotalol hydrochloride therapy to a higher oral dose, the method comprising:
(1) identifying a subject as having symptomatic atrial fibrillation or atrial flutter, who is currently in sinus rhythm, who is under QTc monitoring, and who is receiving 120 mg oral sotalol hydrochloride therapy such that the subject has a concentration of sotalol resulting therefrom;
(2) escalating the concentration of sotalol of the subject to a higher concentration, by administering over a period of 1 hour, a single IV dosage of sotalol hydrochloride in an amount in the range of 99 mg to 105.6 mg and at a rate in the range of 1.65-1.76 mg/min; and
(3) after completion of the single IV dosage of sotalol hydrochloride, increasing the amount of the subject's oral dosing from 120 mg to 160 mg by administering at least one oral dose of 160 mg sotalol hydrochloride to the subject.